Elicio Therapeutics Inc. (ELTX)

US · Healthcare · Biotechnology

$1.86+5.37%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-8.2M

EPS

$-0.43

EPS estimate

$-0.53

EPS came in at -0.43 against a street estimate of -0.53 — a beat of 18.9%.

Market cap

$53.9M

Forward P/E

0.0

P/B

6.79

Book value

$0.36

EPS (TTM)

$-2.15

52-week high

$16.00

52-week low

$2.02

50-day MA

$2.96

200-day MA

$7.90

Beta

1.86

Analysts rate Elicio Therapeutics Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $16.50.

Insiders

26.97%

Institutions

16.24%

Fund	Stake
Knoll Capital Management LP	2.88%
Vanguard Capital Management, LLC	2.37%
Balyasny Asset Management LLC	1.12%
Geode Capital Management, LLC	0.62%
Renaissance Technologies Corp	0.56%
Marshall Wace Asset Management Ltd	0.34%
Susquehanna International Group, LLP	0.32%
Vanguard Fiduciary Trust Co	0.32%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Elicio Therapeutics Inc. — free to start.

Data updated 2026-09-18.